Syros Pharmaceuticals Inc... (SYRS)
NASDAQ: SYRS
· Real-Time Price · USD
0.03
0.00 (19.52%)
At close: Jun 09, 2025, 3:26 PM
Syros Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 386K | 4.15M | 6.98M | 9.94M | 4.08M | 4.21M | 7.65M | 10.17M | 23.44M | 25.24M | 24.13M | 23.49M | 21.39M | 19.52M | 17.54M |
Cost of Revenue | 1.27M | 1.56M | 1.88M | 2.25M | 2.74M | 2.85M | 2.92M | 2.97M | 2.2M | 1.47M | 747K | n/a | n/a | n/a | n/a |
Gross Profit | -883K | 2.59M | 5.1M | 7.68M | 1.34M | 1.36M | 4.73M | 7.2M | 21.24M | 23.77M | 23.38M | 23.49M | 21.39M | 19.52M | 17.54M |
Operating Income | -111.52M | -119.98M | -126.56M | -128.85M | -137.84M | -142.66M | -142.43M | -135.87M | -125.3M | -112.76M | -105.13M | -99.42M | -103.22M | -95.3M | -85.9M |
Interest Income | 4.71M | 5.55M | 6.59M | 6.82M | 7.13M | 5.88M | 3.87M | 2.13M | 570K | 210K | 110K | 85K | 54K | 22K | 10K |
Pretax Income | -97.81M | -131.56M | -144.49M | -164.57M | -104.96M | -95.07M | -93.3M | -94.65M | -113.69M | -109.47M | -97.48M | -86.56M | -92.88M | -86.33M | -81.04M |
Net Income | -97.81M | -131.56M | -144.49M | -155.71M | -63.75M | -44.66M | -43.59M | -52.31M | -103.7M | -108.67M | -95.97M | -86.56M | -92.88M | -86.33M | -81.04M |
Selling & General & Admin | 23.27M | 25.38M | 27.14M | 28.28M | 29.72M | 30.04M | 29.75M | 29.3M | 28.4M | 25.67M | 24.25M | 23.04M | 22.5M | 22.3M | 21.91M |
Research & Development | 87.69M | 95.45M | 103.43M | 107.87M | 114.56M | 112.04M | 115.53M | 111.94M | 110.83M | 112.33M | 105.01M | 99.87M | 102.1M | 92.52M | 81.53M |
Other Expenses | -21.82M | -19.46M | 2.49M | 2.49M | 11.86M | n/a | n/a | n/a | -9.51M | n/a | n/a | n/a | n/a | -489K | -944K |
Operating Expenses | 110.97M | 123.18M | 132.93M | 138.51M | 146.64M | 142.08M | 145.29M | 141.24M | 139.22M | 138M | 129.26M | 122.91M | 124.6M | 114.82M | 103.44M |
Interest Expense | 5.33M | 5.32M | 5.22M | 5.13M | 4.92M | 4.67M | 4.38M | 4.13M | 3.99M | 3.93M | 3.92M | 3.91M | 2.92M | 1.94M | 967K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 111.91M | 124.13M | 133.54M | 138.79M | 146.64M | 142.08M | 145.29M | 141.24M | 139.22M | 138M | 129.26M | 122.91M | 124.6M | 114.82M | 103.44M |
Income Tax Expense | 11.17M | 7.88M | 9.16M | n/a | -43.23M | -49.14M | -49.7M | -42.34M | -9.01M | 1.18M | 1.43M | 3.91M | 4.34M | 3.35M | 2.38M |
Shares Outstanding (Basic) | 39.27M | 39.27M | 38.98M | 29.54M | 27.99M | 27.91M | 27.84M | 27.75M | 9.42M | 6.38M | 6.31M | 6.29M | 6.29M | 6.25M | 6.14M |
Shares Outstanding (Diluted) | 39.34M | 39.27M | 38.98M | 29.54M | 27.99M | 27.91M | 27.84M | 27.75M | 9.42M | 6.38M | 6.31M | 6.29M | 6.29M | 6.29M | 6.14M |
EPS (Basic) | -3.03 | -4.3 | -5.01 | -5.45 | -2.28 | -3.09 | -7.3 | -10.51 | -15.28 | -17.18 | -15.27 | -13.84 | -14.97 | -15.09 | -15.25 |
EPS (Diluted) | -3.03 | -4.3 | -5.01 | -5.45 | -2.28 | -3.09 | -7.3 | -10.51 | -15.28 | -17.18 | -15.25 | -13.82 | -14.95 | -15.07 | -15.25 |
EBITDA | -91.22M | -124.68M | -137.39M | -157.19M | -97.3M | -87.55M | -86M | -87.55M | -106.73M | -102.53M | -90.53M | -79.63M | -86.03M | -79.98M | -75.19M |
EBIT | -92.48M | -126.24M | -139.28M | -159.45M | -100.04M | -90.4M | -88.92M | -90.52M | -109.7M | -105.54M | -93.56M | -82.65M | -88.99M | -82.95M | -78.17M |
Depreciation & Amortization | 1.27M | 1.56M | 1.88M | 2.25M | 2.74M | 2.85M | 2.92M | 2.97M | 2.97M | 3.01M | 3.04M | 3.02M | 3.02M | 3.02M | 3.02M |